National Cancer Institute National Cancer Institute
U.S. National Institutes of Health National Cancer Institute
Search
NCI Home Cancer Topics Clinical Trials Cancer Statistics Research & Funding News About NCI
Mistletoe Extracts (PDQ®)
Patient VersionHealth Professional VersionLast Modified: 04/23/2008



Purpose of This Summary






Overview






General Information






History






Laboratory/Animal/Preclinical Studies






Human/Clinical Studies







Adverse Effects






Overall Level of Evidence for Mistletoe Extracts






Changes to This Summary (04/23/2008)






More Information



Page Options
Print This Page  Print This Page
Print This Document  Print Entire Document
View Entire Document  View Entire Document
E-Mail This Document  E-Mail This Document
Quick Links
Director's Corner

Dictionary of Cancer Terms

NCI Drug Dictionary

Funding Opportunities

NCI Publications

Advisory Boards and Groups

NIH Calendar of Events

Español
NCI Highlights
New Study of Targeted Therapies for Breast Cancer

The Nation's Investment in Cancer Research FY 2009

President's Cancer Panel Annual Report: 2006-2007

Cancer Trends Progress Report: 2007 Update

Past Highlights
HPV Vaccines for Cervical Cancer
Adverse Effects

Although a number of different mistletoe extracts have been used in human studies, the reported side effects have generally been minimal and not life threatening. Common side effects include soreness and inflammation at injection sites, headache, fever, and chills. Reviewed in [1-3] A few cases of severe allergic reactions, including anaphylactic shock, have been reported.[2]

In contrast, mistletoe plants and berries are considered poisonous. Seizures, vomiting, and death have been reported following ingestion of these substances. Reviewed in [1,4] The severity of the toxic effects associated with mistletoe ingestion may depend on the amount consumed and the type of mistletoe plant. Reviewed in [4]

References

  1. Kaegi E: Unconventional therapies for cancer: 3. Iscador. Task Force on Alternative Therapies of the Canadian Breast Cancer Research Initiative. CMAJ 158 (9): 1157-9, 1998.  [PUBMED Abstract]

  2. Hutt N, Kopferschmitt-Kubler M, Cabalion J, et al.: Anaphylactic reactions after therapeutic injection of mistletoe (Viscum album L.). Allergol Immunopathol (Madr) 29 (5): 201-3, 2001 Sep-Oct.  [PUBMED Abstract]

  3. Stauder H, Kreuser ED: Mistletoe extracts standardised in terms of mistletoe lectins (ML I) in oncology: current state of clinical research. Onkologie 25 (4): 374-80, 2002.  [PUBMED Abstract]

  4. Hall AH, Spoerke DG, Rumack BH: Assessing mistletoe toxicity. Ann Emerg Med 15 (11): 1320-3, 1986.  [PUBMED Abstract]

Back to TopBack to Top

< Previous Section  |  Next Section >


A Service of the National Cancer Institute
Department of Health and Human Services National Institutes of Health USA.gov